Its potential role in SMA therapy was deepened by Farooq’s lab, which focused on p38 MAPK pathway and showed that it upregulates cytoplasmic HuR protein, in turn able to stabilize mRNA-binding, also involving SMN (Farooq et al., 2013). The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.